CN103687856B - 用于治疗糖尿病的新的1,2,3,4-四氢喹啉衍生物 - Google Patents
用于治疗糖尿病的新的1,2,3,4-四氢喹啉衍生物 Download PDFInfo
- Publication number
- CN103687856B CN103687856B CN201280036072.0A CN201280036072A CN103687856B CN 103687856 B CN103687856 B CN 103687856B CN 201280036072 A CN201280036072 A CN 201280036072A CN 103687856 B CN103687856 B CN 103687856B
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- diabetes
- acceptable salt
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161524462P | 2011-08-17 | 2011-08-17 | |
| US61/524,462 | 2011-08-17 | ||
| PCT/US2012/050051 WO2013025424A1 (en) | 2011-08-17 | 2012-08-09 | A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103687856A CN103687856A (zh) | 2014-03-26 |
| CN103687856B true CN103687856B (zh) | 2015-07-22 |
Family
ID=46690732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280036072.0A Expired - Fee Related CN103687856B (zh) | 2011-08-17 | 2012-08-09 | 用于治疗糖尿病的新的1,2,3,4-四氢喹啉衍生物 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8431706B2 (https=) |
| EP (1) | EP2744806B1 (https=) |
| JP (1) | JP5903162B2 (https=) |
| KR (1) | KR101570624B1 (https=) |
| CN (1) | CN103687856B (https=) |
| AP (1) | AP3589A (https=) |
| AR (1) | AR087451A1 (https=) |
| AU (1) | AU2012295372A1 (https=) |
| BR (1) | BR112014003079A2 (https=) |
| CA (1) | CA2843474C (https=) |
| CL (1) | CL2014000357A1 (https=) |
| CO (1) | CO6880069A2 (https=) |
| CR (1) | CR20140052A (https=) |
| DO (1) | DOP2014000018A (https=) |
| EA (1) | EA022165B1 (https=) |
| EC (1) | ECSP14013211A (https=) |
| ES (1) | ES2578165T3 (https=) |
| GT (1) | GT201400022A (https=) |
| IL (1) | IL230635A (https=) |
| IN (1) | IN2014MN00191A (https=) |
| MA (1) | MA35351B1 (https=) |
| MX (1) | MX2014001832A (https=) |
| PE (1) | PE20140831A1 (https=) |
| PH (1) | PH12014500366A1 (https=) |
| SG (1) | SG11201401793PA (https=) |
| TN (1) | TN2014000058A1 (https=) |
| TW (1) | TWI537262B (https=) |
| UA (1) | UA110983C2 (https=) |
| WO (1) | WO2013025424A1 (https=) |
| ZA (1) | ZA201400705B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2013MU03577A (https=) | 2013-11-14 | 2015-07-31 | Cadila Healthcare Ltd | |
| EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP3102198B1 (en) | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CN109666027A (zh) * | 2017-10-17 | 2019-04-23 | 中国科学院上海药物研究所 | 一类酰胺结构的gpr40激动剂化合物及其用途 |
| US11964938B2 (en) | 2018-01-08 | 2024-04-23 | Celon Pharma S.A. | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| US12516036B2 (en) | 2019-05-31 | 2026-01-06 | Hyundai Pharm Co., Ltd. | Crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative |
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| WO2021083270A1 (zh) * | 2019-10-31 | 2021-05-06 | 中国石油化工股份有限公司 | 负载型催化剂及其制备方法和应用 |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| KR102699076B1 (ko) * | 2021-04-01 | 2024-08-27 | 현대약품 주식회사 | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 |
| CN115317484B (zh) * | 2022-08-26 | 2023-07-18 | 北京箭牧科技有限公司 | Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用 |
| CN115671105B (zh) * | 2022-11-22 | 2023-10-27 | 北京箭牧科技有限公司 | Ly2922470在制备预防或治疗肾脏疾病药物中的应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1318058A (zh) * | 1998-09-17 | 2001-10-17 | 辉瑞产品公司 | 用作cetp抑制剂的4－羧基氨基－2－取代的－1,2,3,4－四氢喹啉 |
| CN1318057A (zh) * | 1998-09-17 | 2001-10-17 | 辉瑞产品公司 | 用作cetp抑制剂的4－氨基取代的－2－取代的－1,2,3,4－四氢喹啉 |
| CN1494542A (zh) * | 2001-03-27 | 2004-05-05 | ������˹ҩƷ��˾ | 作为尾加压素ii受体拮抗剂的1,2,3,4-四氢异喹啉的衍生物 |
| US20060004012A1 (en) * | 2004-02-27 | 2006-01-05 | Michelle Akerman | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| US20110092531A1 (en) * | 2009-10-15 | 2011-04-21 | Eli Lilly And Company | Novel Spiropiperidine Compounds |
| WO2011066183A1 (en) * | 2009-11-30 | 2011-06-03 | Eli Lilly And Company | Novel spiropiperidine compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7786165B2 (en) * | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| JP4859665B2 (ja) * | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
-
2012
- 2012-08-03 TW TW101128102A patent/TWI537262B/zh not_active IP Right Cessation
- 2012-08-03 AR ARP120102845A patent/AR087451A1/es unknown
- 2012-08-09 EA EA201490269A patent/EA022165B1/ru not_active IP Right Cessation
- 2012-08-09 WO PCT/US2012/050051 patent/WO2013025424A1/en not_active Ceased
- 2012-08-09 MX MX2014001832A patent/MX2014001832A/es unknown
- 2012-08-09 CA CA2843474A patent/CA2843474C/en not_active Expired - Fee Related
- 2012-08-09 SG SG11201401793PA patent/SG11201401793PA/en unknown
- 2012-08-09 JP JP2014526078A patent/JP5903162B2/ja not_active Expired - Fee Related
- 2012-08-09 AP AP2014007436A patent/AP3589A/xx active
- 2012-08-09 PH PH1/2014/500366A patent/PH12014500366A1/en unknown
- 2012-08-09 KR KR1020147003634A patent/KR101570624B1/ko not_active Expired - Fee Related
- 2012-08-09 PE PE2014000218A patent/PE20140831A1/es not_active Application Discontinuation
- 2012-08-09 AU AU2012295372A patent/AU2012295372A1/en not_active Abandoned
- 2012-08-09 CN CN201280036072.0A patent/CN103687856B/zh not_active Expired - Fee Related
- 2012-08-09 US US13/570,342 patent/US8431706B2/en not_active Expired - Fee Related
- 2012-08-09 ES ES12748334.5T patent/ES2578165T3/es active Active
- 2012-08-09 EP EP12748334.5A patent/EP2744806B1/en active Active
- 2012-08-09 UA UAA201401073A patent/UA110983C2/uk unknown
- 2012-08-09 BR BR112014003079A patent/BR112014003079A2/pt not_active IP Right Cessation
-
2013
- 2013-01-30 CR CR20140052A patent/CR20140052A/es unknown
-
2014
- 2014-01-23 IL IL230635A patent/IL230635A/en not_active IP Right Cessation
- 2014-01-28 DO DO2014000018A patent/DOP2014000018A/es unknown
- 2014-01-29 ZA ZA2014/00705A patent/ZA201400705B/en unknown
- 2014-01-30 IN IN191MUN2014 patent/IN2014MN00191A/en unknown
- 2014-02-10 TN TNP2014000058A patent/TN2014000058A1/en unknown
- 2014-02-13 MA MA36755A patent/MA35351B1/fr unknown
- 2014-02-13 GT GT201400022A patent/GT201400022A/es unknown
- 2014-02-13 CL CL2014000357A patent/CL2014000357A1/es unknown
- 2014-02-14 CO CO14032116A patent/CO6880069A2/es active IP Right Grant
- 2014-02-17 EC ECSP14013211 patent/ECSP14013211A/es unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1318058A (zh) * | 1998-09-17 | 2001-10-17 | 辉瑞产品公司 | 用作cetp抑制剂的4－羧基氨基－2－取代的－1,2,3,4－四氢喹啉 |
| CN1318057A (zh) * | 1998-09-17 | 2001-10-17 | 辉瑞产品公司 | 用作cetp抑制剂的4－氨基取代的－2－取代的－1,2,3,4－四氢喹啉 |
| CN1494542A (zh) * | 2001-03-27 | 2004-05-05 | ������˹ҩƷ��˾ | 作为尾加压素ii受体拮抗剂的1,2,3,4-四氢异喹啉的衍生物 |
| US20060004012A1 (en) * | 2004-02-27 | 2006-01-05 | Michelle Akerman | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| US20110092531A1 (en) * | 2009-10-15 | 2011-04-21 | Eli Lilly And Company | Novel Spiropiperidine Compounds |
| WO2011066183A1 (en) * | 2009-11-30 | 2011-06-03 | Eli Lilly And Company | Novel spiropiperidine compounds |
Non-Patent Citations (1)
| Title |
|---|
| 基于四氢喹啉酸骈环戊烯骨架的蛋白酪氨酸磷酸酶1B抑制剂的设计、合成及构效关系;柴茜，等;《高等学校化学学报》;20110228;第32卷(第2期);第306-315页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103687856B (zh) | 用于治疗糖尿病的新的1,2,3,4-四氢喹啉衍生物 | |
| CN102648195B (zh) | 新的螺哌啶化合物 | |
| JP5524091B2 (ja) | エストロゲン関連受容体モジュレータ化合物及びその使用 | |
| JP5269085B2 (ja) | ヒト免疫不全ウイルス複製のインヒビター | |
| JP5269087B2 (ja) | ヒト免疫不全ウイルス複製のインヒビター | |
| JP5244589B2 (ja) | イミダゾールに基づくｌｘｒモジュレーター | |
| JP5269086B2 (ja) | ヒト免疫不全ウイルスの複製阻害薬 | |
| ES2728199T3 (es) | Indazoles sustituidos con amida como inhibidores de poli (ADP-ribosa) polimerasa (PARP) | |
| CA2971125C (en) | Urat1 inhibitor | |
| EP2683690A1 (en) | Quinolinone derivatives | |
| CA2469048A1 (en) | Quinolinones as prostaglandin receptor ligands | |
| TW201625610A (zh) | 萘啶二酮（ｎａｐｈｔｈｙｒｉｄｉｎｅｄｉｏｎｅ）衍生物 | |
| JP2010504321A (ja) | インスリン抵抗性または高血糖に関連する代謝性障害の治療のためのピリジン誘導体 | |
| BRPI0609207A2 (pt) | derivados de Ácido pirimidincarboxÍlico e seu uso | |
| WO2014117292A1 (zh) | 酰胺类化合物及其制备方法、药物组合物和用途 | |
| KR20250004039A (ko) | Tead 억제제로서 바이사이클 화합물 | |
| NZ621248B2 (en) | A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes | |
| WO2005017185A2 (en) | HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS | |
| CN101528734B (zh) | 治疗代谢障碍的3-氨基吡啶衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140326 Assignee: JIANGSU TASLY DIYI PHARMACEUTICAL Co.,Ltd. Assignor: Eli Lilly and Co. Contract record no.: 2018990000174 Denomination of invention: Fixed zymological method for production of prostaglandin E* Granted publication date: 20150722 License type: Exclusive License Record date: 20180704 |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150722 |